|
|
Volumn 70, Issue 5, 2012, Pages 699-705
|
|
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
a
b
a
|
|
Author keywords
IHL 305; PEGylated liposomal irinotecan; Pharmacokinetic; Phase I
|
|
Indexed keywords
FIRTECAN;
GLUCURONOSYLTRANSFERASE 1A1;
IHL 305;
IRINOTECAN;
PEGYLATED LIPOSOMAL IRINOTECAN;
UNCLASSIFIED DRUG;
ADULT;
ADVANCED CANCER;
AGED;
ALLELE;
ALOPECIA;
ANEMIA;
ANOREXIA;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
BLADDER CANCER;
BREAST CANCER;
CHEMOTHERAPY INDUCED EMESIS;
COLORECTAL CANCER;
CONSTIPATION;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DEHYDRATION;
DIARRHEA;
DRUG BLOOD LEVEL;
DRUG DOSE ESCALATION;
DRUG EXPOSURE;
DRUG RELEASE;
DRUG RESPONSE;
DRUG SAFETY;
DRUG TOLERABILITY;
FATIGUE;
FEBRILE NEUTROPENIA;
FEMALE;
GENOTYPE;
HEAD AND NECK CANCER;
HOMOZYGOSITY;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MALE;
MAXIMUM TOLERATED DOSE;
NAUSEA;
NEUROENDOCRINE TUMOR;
NEUTROPENIA;
OVARY CANCER;
PANCREAS CANCER;
PERIPHERAL EDEMA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
SOLID TUMOR;
THROMBOCYTOPENIA;
WILD TYPE;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
CAMPTOTHECIN;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
GLUCURONOSYLTRANSFERASE;
HUMANS;
LIPOSOMES;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
NEOPLASMS;
POLYETHYLENE GLYCOLS;
TREATMENT OUTCOME;
|
|
EID: 84871191244
PISSN: 03445704
EISSN: 14320843
Source Type: Journal
DOI: 10.1007/s00280-012-1960-5 Document Type: Article |
|
Times cited : (42)
|
|
References (11)
|
